Invitrogen opens Australian cGMP manufacturing facility

Thursday, 25 August, 2005

Invitrogen has opened a AU$3.4 million cGMP bioproduction facility focused on the development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.

cGMP refers to good manufacturing practices required in the design and operation of the facility, processes and quality systems in order to serve global pharmaceutical companies. Invitrogen's site also features new process technology and automation optimised for the standards expected by biopharmaceutical customers.

Australia and New Zealand are among the few countries regarded as being BSE free, as well as having a lower incidence of other viral diseases prevalent in other countries. As a result, global pharmaceutical companies are seeking secure supply of locally produced biotechnology products.

This reputation is important as it encourages global biopharmaceutical customers to source product from this part of the world. It is a global advantage that may encourage Invitrogen to continue to review opportunities to expand its operations in Australia.

Related News

IDT and 3CR collaborate on custom genotyping service

The partnership fuses IDT's oligo synthesis with 3CR's PACE Genotyping Master Mix and...

$6m investment in WA space sector

Western Australia will play a key role in the Australian Space Agency's efforts to triple the...

Nominations for Fresh Science 2019 now open

Fresh Science helps researchers find the key, compelling 'story' in their work and then...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd